{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Shyr D"],"pubmed_abstract":["<h4>Importance</h4>Cancer survivors have increased cardiovascular disease (CVD) risk partly due to the toxic effects of cancer therapy. Clonal hematopoiesis of indeterminate potential (CHIP), an age-associated blood disorder caused by somatic variants in blood stem cells, is more prevalent among individuals receiving cancer therapy and increases CVD risk independent of traditional risk factors. It is unknown whether CHIP amplifies therapy-related cardiovascular toxic effects in patients with cancer.<h4>Objective</h4>To assess the association between CHIP and CVD risk, accounting for competing risks, among patients with primary solid tumors who received chemotherapy, radiotherapy, or immunotherapy.<h4>Design, setting, and participants</h4>A cohort study was conducted using BioVU, Vanderbilt"],"journal":["JAMA oncology"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12784258"],"repository":["biostudies-literature"],"pubmed_title":["Clonal Hematopoiesis and Cardiovascular Disease Risk After Cancer Therapy in Patients With Solid Tumors."],"pmcid":["PMC12784258"],"pubmed_authors":["Shinohara E","Kishtagari A","Shyr D","Luo L","Pershad Y","Heimlich JB","Bick AG","Zhao K","Park BH","Corty RW"],"additional_accession":[]},"is_claimable":false,"name":"Clonal Hematopoiesis and Cardiovascular Disease Risk After Cancer Therapy in Patients With Solid Tumors.","description":"<h4>Importance</h4>Cancer survivors have increased cardiovascular disease (CVD) risk partly due to the toxic effects of cancer therapy. Clonal hematopoiesis of indeterminate potential (CHIP), an age-associated blood disorder caused by somatic variants in blood stem cells, is more prevalent among individuals receiving cancer therapy and increases CVD risk independent of traditional risk factors. It is unknown whether CHIP amplifies therapy-related cardiovascular toxic effects in patients with cancer.<h4>Objective</h4>To assess the association between CHIP and CVD risk, accounting for competing risks, among patients with primary solid tumors who received chemotherapy, radiotherapy, or immunotherapy.<h4>Design, setting, and participants</h4>A cohort study was conducted using BioVU, Vanderbilt","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-09T05:32:19.038Z","creation":"2026-06-09T03:07:03.559Z"},"accession":"S-EPMC12784258","cross_references":{"pubmed":["41505144"],"doi":["10.1001/jamaoncol.2025.5785"]}}